Skip to main content
English
Català
Čeština
Deutsch
Español
Français
Gàidhlig
Italiano
Latviešu
Magyar
Nederlands
Polski
Português
Português do Brasil
Srpski (lat)
Suomi
Svenska
Türkçe
Tiếng Việt
Қазақ
বাংলা
हिंदी
Ελληνικά
Српски
Yкраї́нська
Log In
Email address
Password
Log in
Have you forgotten your password?
Communities & Collections
All Contents
Statistics
English
Català
Čeština
Deutsch
Español
Français
Gàidhlig
Italiano
Latviešu
Magyar
Nederlands
Polski
Português
Português do Brasil
Srpski (lat)
Suomi
Svenska
Türkçe
Tiếng Việt
Қазақ
বাংলা
हिंदी
Ελληνικά
Српски
Yкраї́нська
Log In
Email address
Password
Log in
Have you forgotten your password?
Home
Araştırma Çıktıları | Web Of Science
Web of Science Koleksiyonu
English
English
No Thumbnail Available
Date
Authors
Saruc, M
Ozden, N
Turkel, N
Ayhan, S
Hock, LM
Tuzcuoglu, I
Yuceyar, H
Journal Title
Journal ISSN
Volume Title
Publisher
0022-3549
Abstract
ELSEVIER SCIENCE INC
Description
Keywords
Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and thymosin-alpha1 compared with lamivudine plus interferon alpha-2b and interferon alpha-2b alone. Fifty-two patients with HbeAg-negative chronic hepatitis B were assigned to three different groups in a nonrandomized manner. Group 1 (n = 27) received thymosin-alpha1 [1.6 mg subcutaneously (sc), twice a week] and interferon alpha-2b (10 MIU sc, three times per week) for 26 weeks, subsequently followed by interferon alpha-2b monotherapy at the same dosage for an additional 26 weeks. Group 2 (n = 10) received interferon alpha-2b (10 MIU sc, three times per week) for 52 weeks. Group 3 (n = 15) received interferon a-2b (10 MIU sc, three times per week) and lamivudine [100 mg orally (po), q.d.] for, 62 weeks, followed by continuous lamivudine (100 mg po, q.d.) therapy. By the end of 78 weeks, a sustained response (SR-6 mo) was seen in 74% (20/27) of the patients within Group 1. On the contrary, Groups 2 and 3 had sustained response rates of 40 (4/10) and 53.3% (8/15), respectively (p = 0.13). At the end of 12 months post-treatment in Group 1, a virological and biochemical response rate was seen in 70.3% of patients (19/27); in contrast, Groups 2 and 3 had response rates of 20 (2/10) and 26.6% (4/15), respectively (p = 0036). At the end of the 18-month post-treatment follow-up period, 71.4% (19/27) of patients in Group 1, 10% of patients in Group 2 (1/10), and 20% of patients in Group 3(3/15) preserved their sustained response (p = 0.0003). Interferon alpha-2b and thymosin-alpha1 combination therapy results in significant virological and biochemical response rates compared with standard therapeutic regimens and is well tolerated.
Citation
URI
http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/6562
Collections
Web of Science Koleksiyonu
Full item page